- Home
- GLTO vs PLAG Comparison
GLTO vs PLAG Comparison
Compare GLTO & PLAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- PLAG
- Stock Information
- Founded
- GLTO 2011
- PLAG 1986
- Country
- GLTO Denmark
- PLAG United States
- Employees
- GLTO N/A
- PLAG N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- PLAG Packaged Foods
- Sector
- GLTO Health Care
- PLAG Consumer Staples
- Exchange
- GLTO Nasdaq
- PLAG Nasdaq
- Market Cap
- GLTO 23.7M
- PLAG 23.9M
- IPO Year
- GLTO 2020
- PLAG N/A
- Fundamental
- Price
- GLTO $16.82
- PLAG $2.55
- Analyst Decision
- GLTO
- PLAG
- Analyst Count
- GLTO 0
- PLAG 0
- Target Price
- GLTO N/A
- PLAG N/A
- AVG Volume (30 Days)
- GLTO 3.4M
- PLAG 288.4K
- Earning Date
- GLTO 11-06-2025
- PLAG 11-14-2025
- Dividend Yield
- GLTO N/A
- PLAG N/A
- EPS Growth
- GLTO N/A
- PLAG N/A
- EPS
- GLTO N/A
- PLAG N/A
- Revenue
- GLTO N/A
- PLAG $5,494,847.00
- Revenue This Year
- GLTO N/A
- PLAG N/A
- Revenue Next Year
- GLTO N/A
- PLAG N/A
- P/E Ratio
- GLTO N/A
- PLAG N/A
- Revenue Growth
- GLTO N/A
- PLAG N/A
- 52 Week Low
- GLTO $2.01
- PLAG $0.47
- 52 Week High
- GLTO $33.60
- PLAG $3.28
- Technical
- Relative Strength Index (RSI)
- GLTO 55.60
- PLAG 56.80
- Support Level
- GLTO $15.76
- PLAG $1.29
- Resistance Level
- GLTO $29.03
- PLAG $3.28
- Average True Range (ATR)
- GLTO 4.83
- PLAG 0.50
- MACD
- GLTO -0.52
- PLAG 0.09
- Stochastic Oscillator
- GLTO 43.02
- PLAG 60.80
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About PLAG Planet Green Holdings Corp.
Planet Green Holdings Corp is a diversified technology and consumer products company with a presence in North America and China engaged in Chemical Products, Tea Products, and Online Advertising Services. The company operates in three segments namely to grow, produce, and distribute Cyan brick tea, black tea, and green tea in China; to research, develop, manufacture, and sell chemical products including formaldehyde, urea formaldehyde adhesive, methylal, ethanol fuel, fuel additives and clean fuel in China; and to develop and operate a demand-side platform which empowers buyers of advertising to manage and optimize their digital advertising across different real-time bidding networks in North America and China.